Western blot analysis of tumor tissue lysates revealed that TBOPP treatment obviously suppressed the metformin-induced RAC1 activation (Fig. 4E), which confirmed that RAC1 activation contributes to the DOCK1 suppression associated sensitization of cancer cells to metformin in vivo. The gene discussed is DOCK1; the disease is cancer.